Is Pacritinib approved for myelofibrosis?

What is Pacritinib for myelofibrosis?

Pacritinib is an orally administered JAK2 inhibitor designed to target and selectively inhibit the JAK2 enzyme with high potency, minimal off-target activity at other JAK family members, and a high degree of selectivity against mutant forms of JAK2 that are commonly found in myeloproliferative neoplasms (MPNs) such as myelofibrosis. [1]

Approval status for myelofibrosis

On May 24, 2022, Pacritinib was approved by the United States Food and Drug Administration (FDA) for the treatment of myelofibrosis in adult patients who have previously received ruxolitinib. [2] The approval was based on the results of the PACITY clinical trial.

Pacency Clinical Trial

The PACITY trial was a pivotal Phase 3 clinical trial that compared the efficacy of Pacritinib with best available therapy (BAT) in patients with myelofibrosis. The study demonstrated that Pacritinib produced significant improvements in spleen size reduction, symptom control, and overall quality of life compared to BAT. [1]

What can you expect from Pacritinib?

Pacritinib is taken orally once daily, and it is recommended that the dose be adjusted based on the presence or absence of gastrointestinal side effects. The medication was generally well-tolerated in clinical studies, but nausea, diarrhea, vomiting, and fatigue were the most common adverse events. [1]

Is Pacritinib a good choice for you?

Whether or not Pacritinib is a good choice for you depends on your individual needs and medical history. You should consult with your healthcare provider to discuss the potential benefits and risks of Pacritinib treatment.

Sources

[1] - https://www.drugpatentwatch.com/drug/Pacritinib

[2] - https://www.accessdata.fda.gov/cder/foi/label/2022/207994Orig1s000lb.pdf

[3] - https://www.drugpatentwatch.com/drug/Pacritinib